Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All iota‑carrageenan studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina

Chahla et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433, NCT04701710
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Moderate/severe case 95% Improvement Relative Risk Case 84% Iota-carrageenan  Chahla et al.  Prophylaxis  RCT Is prophylaxis with iota-carrageenan + ivermectin beneficial for COVID-19? RCT 234 patients in Argentina (October - December 2020) Fewer moderate/severe cases (p=0.0016) and cases (p=0.004) c19early.org Chahla et al., American J. Therapeutics, Jan 2021 Favors carrageenan Favors control
Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases with treatment vs. 10 in the control group. There were 4 cases with treatment (all mild) vs. 25 for the control group.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
Study covers iota-carrageenan and ivermectin.
risk of moderate/severe case, 95.2% lower, RR 0.05, p = 0.002, treatment 0 of 117 (0.0%), control 10 of 117 (8.5%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate/severe COVID-19.
risk of case, 84.0% lower, RR 0.16, p = 0.004, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), NNT 5.6, adjusted per study, odds ratio converted to relative risk, all cases.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chahla et al., 11 Jan 2021, Randomized Controlled Trial, Argentina, peer-reviewed, 11 authors, study period 15 October, 2020 - 31 December, 2020, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary, trial NCT04701710 (history).
This PaperIota-carragee..All
Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina
tive effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Rossana E. Chahla, MD, PhD 1 Luis Medina Ruiz, MD 2 Eugenia S. Ortega, MSc 3 Marcelo F. Morales, RN 4 Francisco Barreiro, MD 5 Alexia George, MD 5 Cesar Mancilla, RN 4 Sylvia D' Amato, RN 4 Guillermo Barrenechea, MSc 3 Daniel G. Goroso, PhD
References
Abd-Elsalam, Noor, Badawi, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study
Alam, Murshed, Gomes, Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in dhakaan observational study, Eur J Med Heal Sci
Ashburn, Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov
Caly, Druce, Catton, Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , the company' s public news and information, Antivir Res
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antivir Res
Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: a pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine
Chaccour, Ruiz-Castillo, Richardson, The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol, Trials
Chahla, Prophylaxis covid-19 in health workers through intensive treatment with ivermectin and iotacarrageenan (Ivercar-Tuc), ClinicalTrials
Chong, Sullivan, New uses for old drugs, Nature
H Ector, Roberto, Psaltis, Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Investig
Hirsch, Hector, Covid 19 and ivermectin prevention and treatment update, J Infect Dis Trav Med
Kory, Meduri, Varon, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial, EClinicalMedicine
Liu, Fang, Reagan, In silico drug repositioning: what we need to know, Drug Discov Today
Shouman, Hegazy, Nafae, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial, J Clin Diagn Res
{ 'indexed': {'date-parts': [[2022, 7, 11]], 'date-time': '2022-07-11T06:51:07Z', 'timestamp': 1657522267235}, 'reference-count': 18, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1097/mjt.0000000000001433', 'type': 'journal-article', 'created': {'date-parts': [[2021, 9, 2]], 'date-time': '2021-09-02T00:35:39Z', 'timestamp': 1630542939000}, 'page': 'e601-e604', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for ' 'COVID-19 in Health Care Workers From Tucuman, Argentina', 'prefix': '10.1097', 'volume': '28', 'author': [ {'given': 'Rossana E.', 'family': 'Chahla', 'sequence': 'first', 'affiliation': []}, {'given': 'Luis', 'family': 'Medina Ruiz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eugenia S.', 'family': 'Ortega', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marcelo F.', 'family': 'Morales, RN', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francisco', 'family': 'Barreiro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexia', 'family': 'George', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cesar', 'family': 'Mancilla, RN', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sylvia', 'family': "D' Amato, RN", 'sequence': 'additional', 'affiliation': []}, {'given': 'Guillermo', 'family': 'Barrenechea', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniel G.', 'family': 'Goroso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria', 'family': 'Peral de Bruno', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2021, 9]]}, 'reference': [ { 'key': 'R1-20210907', 'doi-asserted-by': 'crossref', 'first-page': '645', 'DOI': '10.1038/448645a', 'article-title': 'New uses for old drugs', 'volume': '448', 'author': 'Chong', 'year': '2007', 'journal-title': 'Nature.'}, { 'key': 'R2-20210907', 'doi-asserted-by': 'crossref', 'first-page': '110', 'DOI': '10.1016/j.drudis.2012.08.005', 'article-title': 'In silico drug repositioning: what we need to know', 'volume': '18', 'author': 'Liu', 'year': '2013', 'journal-title': 'Drug Discov Today'}, { 'key': 'R3-20210907', 'doi-asserted-by': 'crossref', 'first-page': '673', 'DOI': '10.1038/nrd1468', 'article-title': 'Drug repositioning: identifying and developing new uses for existing ' 'drugs', 'volume': '3', 'author': 'Ashburn', 'year': '2004', 'journal-title': 'Nat Rev Drug Discov.'}, { 'key': 'R4-20210907', 'doi-asserted-by': 'crossref', 'first-page': '202', 'DOI': '10.1016/j.antiviral.2012.06.008', 'article-title': 'Nuclear trafficking of proteins from RNA viruses: potential target for ' 'antivirals?', 'volume': '95', 'author': 'Caly', 'year': '2012', 'journal-title': 'Antivir Res'}, { 'key': 'R5-20210907', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'Since January 2020 Elsevier has created a COVID-19 resource centre with ' 'free information in English and Mandarin on the novel coronavirus ' 'COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , ' "the company' s public news and information", 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antivir Res'}, { 'key': 'R6-20210907', 'doi-asserted-by': 'crossref', 'first-page': 'e299', 'DOI': '10.1097/MJT.0000000000001377', 'article-title': 'Review of the emerging evidence demonstrating the efficacy of ' 'ivermectin in the prophylaxis and treatment of COVID-19', 'volume': '28', 'author': 'Kory', 'year': '2021', 'journal-title': 'Am J Ther.'}, { 'key': 'R7-20210907', 'doi-asserted-by': 'crossref', 'first-page': '100720', 'DOI': '10.1016/j.eclinm.2020.100720', 'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms ' 'and humoral response in patients with non-severe COVID-19: a pilot, ' 'double-blind, placebo-controlled, randomized clinical trial', 'volume': '3', 'author': 'Chaccour', 'year': '2021', 'journal-title': 'EClinicalMedicine.'}, { 'key': 'R8-20210907', 'doi-asserted-by': 'crossref', 'first-page': '100959', 'DOI': '10.1016/j.eclinm.2021.100959', 'article-title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: A ' 'proof-of-concept randomized trial', 'volume': '37', 'author': 'Krolewiecki', 'year': '2021', 'journal-title': 'EClinicalMedicine.'}, { 'key': 'R9-20210907', 'doi-asserted-by': 'crossref', 'first-page': '1007', 'DOI': '10.31546/2633-8653.1007', 'article-title': 'Study of the efficacy and safety of topical ivermectin + ' 'iota-carrageenan in the prophylaxis against COVID-19 in health ' 'personnel', 'volume': '2', 'author': 'Héctor', 'year': '2020', 'journal-title': 'J Biomed Res Clin Investig.'}, { 'key': 'R10-20210907', 'first-page': '1', 'article-title': 'Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare ' 'providers in a selected tertiary hospital in dhaka—an observational ' 'study', 'volume': '2', 'author': 'Alam', 'year': '2020', 'journal-title': 'Eur J Med Heal Sci.'}, { 'key': 'R11-20210907', 'first-page': '27', 'article-title': 'Use of ivermectin as a potential chemoprophylaxis for COVID-19 in ' 'Egypt: a randomized clinical trial', 'volume': '15', 'author': 'Shouman', 'year': '2021', 'journal-title': 'J Clin Diagn Res.'}, { 'key': 'R12-20210907', 'first-page': 'NCT047017', 'article-title': 'Prophylaxis covid-19 in health workers through intensive treatment with ' 'ivermectin and iota-carrageenan (Ivercar-Tuc)', 'volume': '20', 'author': 'Chahla', 'year': '2020', 'journal-title': 'ClinicalTrials.gov.'}, { 'key': 'R13-20210907', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/s13063-020-04421-z', 'article-title': 'The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate ' 'the potential of ivermectin to reduce covid-19 transmission in low ' 'risk, non-severe covid-19 patients in the first 48 hours after symptoms ' 'onset: a structured summary of a study protocol', 'volume': '21', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Trials'}, { 'key': 'R14-20210907', 'first-page': '1', 'article-title': 'Covid 19 and ivermectin prevention and treatment update', 'volume': '4', 'author': 'Hirsch', 'year': '2020', 'journal-title': 'J Infect Dis Trav Med.'}, { 'key': 'R15-20210907', 'article-title': 'Clinical study evaluating the efficacy of ivermectin in COVID-19 ' 'treatment: A randomized controlled study [published online ahead of ' 'print, 2021 Jun 2]', 'author': 'Abd-Elsalam', 'year': '2021', 'journal-title': 'J Med Virol.'}, { 'key': 'R16-20210907', 'doi-asserted-by': 'crossref', 'first-page': '23', 'DOI': '10.1186/s12941-020-00368-w', 'article-title': 'Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19', 'volume': '19', 'author': 'Sharun', 'year': '2020', 'journal-title': 'Ann Clin Microbiol Antimicrob.'}, { 'key': 'R17-20210907', 'doi-asserted-by': 'crossref', 'first-page': '611', 'DOI': '10.3906/sag-2004-145', 'article-title': 'Antiviral treatment of covid-19', 'volume': '50', 'author': 'Şimşek Yavuz', 'year': '2020', 'journal-title': 'Turkish J Med Sci.'}, { 'key': 'R18-20210907', 'doi-asserted-by': 'crossref', 'first-page': 'e434', 'DOI': '10.1097/MJT.0000000000001402', 'article-title': 'Ivermectin for Prevention and Treatment of COVID-19 Infection: A ' 'Systematic Review, Meta-analysis, and Trial Sequential Analysis to ' 'Inform Clinical Guidelines', 'volume': '28', 'author': 'Bryant', 'year': '2021', 'journal-title': 'Am J Ther.'}], 'container-title': 'American Journal of Therapeutics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001433', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 9, 7]], 'date-time': '2021-09-07T20:00:46Z', 'timestamp': 1631044846000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001433'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8, 16]]}, 'references-count': 18, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2021]]}}, 'URL': 'http://dx.doi.org/10.1097/MJT.0000000000001433', 'relation': {}, 'ISSN': ['1075-2765'], 'subject': ['Pharmacology (medical)', 'Pharmacology', 'General Medicine'], 'published': {'date-parts': [[2021, 8, 16]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit